Currently, a phase Ib/II clinical trial in patients with chemo-resistant epithelial ovarian cancer is testing the combination of entinostat, a class 1 HDACi (HDAC1/3 inhibitor), together with avelumab, a humanized antibody targeting PD-L1, showing initial promising results (NCT02915523). Here, CD274 is linked to ovarian carcinoma.